<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335774</url>
  </required_header>
  <id_info>
    <org_study_id>1-2017</org_study_id>
    <nct_id>NCT03335774</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of Hydrocortisone Acetate Suppositories, 25 mg in the Treatment of Symptomatic Internal Hemorrhoids</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of Hydrocortisone Acetate Suppositories, 25 mg Compared to Placebo Suppositories in the Treatment of Symptomatic Internal Hemorrhoids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nivagen Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nivagen Pharmaceuticals Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, multicenter, parallel group study of the
      safety and efficacy of Hydrocortisone Acetate Suppositories, 25 mg compared to placebo
      suppositories in the treatment of symptomatic internal hemorrhoids.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in swelling</measure>
    <time_frame>Days 1, 15</time_frame>
    <description>Anoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bleeding</measure>
    <time_frame>Days 1-29</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in itching</measure>
    <time_frame>Days 1-29</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in swelling</measure>
    <time_frame>Days 1-29</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pain</measure>
    <time_frame>Days 1-29</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in discomfort</measure>
    <time_frame>Days 1-29</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in overall severity</measure>
    <time_frame>Days 1-29</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Internal Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone Acetate Suppository, 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Vehicle) Suppository</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone Acetate Suppository, 25 mg</intervention_name>
    <description>One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).</description>
    <arm_group_label>Hydrocortisone Acetate Suppository, 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Vehicle) Suppository</intervention_name>
    <description>One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).</description>
    <arm_group_label>Placebo (Vehicle) Suppository</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  internal hemorrhoids.

          -  hemorrhoidal bleeding.

          -  male or female aged 18 years and older.

          -  willing to forego the use of non-prescription (OTC) and prescription medication or
             procedures for the treatment of hemorrhoidal disease and/or pain for the duration of
             the study.

          -  agree to not change their diet during the study.

        Exclusion Criteria:

          -  external hemorrhoids.

          -  using other OTC or prescription medications for treatment of hemorrhoidal disease
             and/or pain.

          -  pregnant or nursing female.

          -  received systemic glucocorticoids within the last 2 months prior to starting study.

          -  participated in an investigational drug study within 30 days prior to baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anand Shukla, MS, MBA, Vice President, Research &amp; Development</last_name>
    <phone>1-888-412-3110</phone>
    <email>clinicaltrials@nivagen.com</email>
  </overall_contact>
  <link>
    <url>http://www.nivagen.com</url>
    <description>Nivagen Pharmaceuticals Inc.</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

